This week, there are 16 drugs in the patent and exclusivity list. They are: - PF PRISM CV's INLYTA, containing active ingredient AXITINIB - KALEO INC's AUVI-Q, containing active ingredient EPINEPHRINE - ASTRAZENECA PHARMACEUTICALS LP's BRILINTA, containing active ingredient TICAGRELOR - IPSEN BIOPHARMACEUTICALS INC's ONIVYDE, containing active ingredient IRINOTECAN HYDROCHLORIDE - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's JENTADUETO, containing active ingredient LINAGLIPTIN; METFORMIN HYDROCHLORIDE - BOEHRINGER INGELHEIM's GLYXAMBI, containing active ingredient EMPAGLIFLOZIN; LINAGLIPTIN - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's TRIJARDY XR, containing active ingredient EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's TRADJENTA, containing active ingredient LINAGLIPTIN - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's JENTADUETO XR, containing active ingredient LINAGLIPTIN; METFORMIN HYDROCHLORIDE Read More

This week, there are 8 drugs in the patent and exclusivity list. They are: - KALEO INC's AUVI-Q, containing active ingredient EPINEPHRINE - NOVO NORDISK INC's VICTOZA, containing active ingredient LIRAGLUTIDE - NOVO NORDISK INC's SAXENDA, containing active ingredient LIRAGLUTIDE - BRISTOL MYERS SQUIBB's REVLIMID, containing active ingredient LENALIDOMIDE - CUMBERLAND PHARMACEUTICALS INC's CALDOLOR, containing active ingredient IBUPROFEN - AMERICAN REGENT INC's INJECTAFER, containing active ingredient FERRIC CARBOXYMALTOSE - ALNYLAM PHARMACEUTICALS INC's GIVLAARI, containing active ingredient GIVOSIRAN SODIUM - AADI BIOSCIENCE INC's FYARRO, containing active ingredient SIROLIMUS Read More